Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > We are Due!!
View:
Post by oats on Feb 05, 2021 12:59pm

We are Due!!

“We are very proud of the work that has been conducted so far and believe we are well-positioned to offer an additional tool in the fight against COVID-19, which is having devastating effects worldwide. With the expected completion of the third and fourth goals related to tolerability, safety and efficacy studies with both nave and pre-clinical animal models as early as mid-October, our teams are positioning us to be ahead of schedule. Hoping for favorable pre-clinical results, preparations of a Phase 1/2 clinical trial protocol will be commenced immediately and planned to be submitted to Health Authorities during Q4 2020. Given that yeast beta-glucan is already approved as a pharmaceutical additive, we expect to quickly develop PGX-YBG as a fast-acting inhalable stand-alone therapeutic and/or delivery system to treat severe inflammation observed in COVID-19 patients and other fibrotic end-point disease in the lung,” commented Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro. “We look forward to providing continued updates as we progress through the next milestones of this study.”
Comment by prophetoffacts on Feb 05, 2021 1:20pm
This post has been removed in accordance with Community Policy
Comment by Stinzo on Feb 05, 2021 2:03pm
whats Gilles estimate timeline for that? Thanks Proph
Comment by prophetoffacts on Feb 05, 2021 2:31pm
This post has been removed in accordance with Community Policy
Comment by oats on Feb 05, 2021 2:07pm
Given that we are now a week into February Jenene, are we still deemed to be ahead of schedule, please see below in yellow. Does the company expect to issue any form of update soon?   Oh sorry, I know you can't answer that question due to "selective disclosure" issues.  Let me try this one:  Do you think we will see news in the within 180 days of the last real ...more  
Comment by upside80 on Feb 05, 2021 2:16pm
You can only appreciate how funny this post is if you've called Jenene before, pure gold. 
Comment by trek01 on Feb 05, 2021 2:22pm
Oats, didn't Gagnon say during the presentation that the MHI is publishing the results so he can't give us details.
Comment by Ciao on Feb 05, 2021 2:31pm
Yes (not MHI), we just don't know when McMaster would publish results.
Comment by westcoast1000 on Feb 05, 2021 3:10pm
If we are paying for the trials, we would own the data. Maybe Gilles does not want to upstage his friend, but some disclosure when there are sensible, reilable results is certainly not unreasonable. 
Comment by prophetoffacts on Feb 05, 2021 3:48pm
This post has been removed in accordance with Community Policy
Comment by Ciao on Feb 05, 2021 4:05pm
Trading volumes on the US side has been solid, esp. this week. We definitely need a corporate update on activities to keep our US investors engaged. U.S. Investors have short attention spans (compared to us old timers here), they may move onto the next story stock sooner than later.
Comment by prophetoffacts on Feb 05, 2021 2:35pm
This post has been removed in accordance with Community Policy
Comment by stockfy on Feb 09, 2021 3:50am
Great catch. Thank you.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities